These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17890246)

  • 21. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL; Lee HY; Low SC; Chan LP; Goh NS; Pang SM
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Case-control study of gadodiamide-related nephrogenic systemic fibrosis.
    Marckmann P; Skov L; Rossen K; Heaf JG; Thomsen HS
    Nephrol Dial Transplant; 2007 Nov; 22(11):3174-8. PubMed ID: 17483196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.
    Chewning RH; Murphy KJ
    J Vasc Interv Radiol; 2007 Mar; 18(3):331-3. PubMed ID: 17377176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.
    Collidge TA; Thomson PC; Mark PB; Traynor JP; Jardine AG; Morris ST; Simpson K; Roditi GH
    Radiology; 2007 Oct; 245(1):168-75. PubMed ID: 17704357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A; Fogel M; Cowper SE
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.
    Yerram P; Saab G; Karuparthi PR; Hayden MR; Khanna R
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):258-63. PubMed ID: 17699422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Nephrogenic systemic fibrosis: more hard times for renal failure patients].
    Plamondon I; Samson C; Watters AK; Bégin LR; Côté J; Déziel C; Quérin S
    Nephrol Ther; 2007 Jul; 3(4):152-6. PubMed ID: 17658442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
    Khurana A; Greene JF; High WA
    J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.
    Khurram M; Skov L; Rossen K; Thomsen HS; Marckmann P
    Scand J Urol Nephrol; 2007; 41(6):565-6. PubMed ID: 17934986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nephrogenic systemic fibrosis: a dermatologist's perspective.
    Girardi M
    J Am Coll Radiol; 2008 Jan; 5(1):40-4. PubMed ID: 18180008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
    Broome DR
    Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephrogenic systemic fibrosis associated with liver transplantation, renal failure and gadolinium.
    Caccetta T; Chan JJ
    Australas J Dermatol; 2008 Feb; 49(1):48-51. PubMed ID: 18186850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease.
    Shenoy C
    Am J Med; 2008 Jan; 121(1):e11; author reply e13. PubMed ID: 18187056
    [No Abstract]   [Full Text] [Related]  

  • 38. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J; Snow T; Hiremagalur B
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M; Uder M
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Nephrogenic systemic fibrosis possibly caused by gadolinium-containing contrast agent].
    van der Meij N; Keur I; van Lienden KP; Scheepstra CG; Bos JD
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2898-903. PubMed ID: 18257437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.